Karolin A, Genitsch V, Sidler D. Calcineurin inhibitor toxicity in solid organ transplantation. Pharmacology. 2021;106:347–355

Article  CAS  PubMed  Google Scholar 

De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of everolimus in liver transplantation: recommendations from a Working Group. Transplantation. 2017;101:239–251

Article  PubMed  Google Scholar 

Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol. 2017;9:990–1000

Article  PubMed Central  PubMed  Google Scholar 

Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation. 2021;105:1564–1575

Article  CAS  PubMed  Google Scholar 

Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 2020;14:930–943

Article  PubMed  Google Scholar 

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3 rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406

Article  PubMed  Google Scholar 

Adam R, Karam V, Cailliez V, Mirza D, Cherqui D, Klempnauer J, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int. 2018;31:1293–1317

Article  PubMed  Google Scholar 

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3:337–348

Article  PubMed  Google Scholar 

Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–207

Article  PubMed  Google Scholar 

Iesari S, Mocchegiani F, Nicolini D, Benedetti Cacciaguerra A, Coletta M, Montalti R, et al. Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: report of a first case. Am J Transplant. 2019;19:2939–2943

Article  PubMed  Google Scholar 

Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16:2892–2902

Article  CAS  PubMed  Google Scholar 

Dueland S, Foss A, Solheim JM, Hagness M, Line PD. Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. Br J Surg. 2018;105:736–742

Article  CAS  PubMed  Google Scholar 

Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open. 2020;4:467–477

Article  CAS  PubMed Central  PubMed  Google Scholar 

Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era–recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. 2005;41:1031–1036

Article  PubMed  Google Scholar 

Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361–371

Article  CAS  PubMed  Google Scholar 

Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20:333–347

Article  PubMed  Google Scholar 

Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Cancers. 2021;13:4882

Article  PubMed Central  PubMed  Google Scholar 

Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039–1049

Article  CAS  PubMed  Google Scholar 

Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125

Article  CAS  PubMed  Google Scholar 

Wei Q, Xu X, Wang C, Zhuang R, Zhuang L, Zhou L, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma. Gut Liver. 2016;10:604–610

Article  PubMed Central  PubMed  Google Scholar 

Lai Q, Iesari S, Finkenstedt A, Hoppe-Lotichius M, Foguenne M, Lehner K, et al. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: a multicenter European experience. Hepatobiliary Pancreat Dis Int. 2019;18:517–524

Article  PubMed  Google Scholar 

Mantel HT, Westerkamp AC, Adam R, Bennet WF, Seehofer D, Settmacher U, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS ONE. 2016;11: e0156127

Article  PubMed Central  PubMed  Google Scholar 

Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104:1125–1130

Article  PubMed  Google Scholar 

Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:364–377

Article  PubMed  Google Scholar 

Kitajima T, Hibi T, Moonka D, Sapisochin G, Abouljoud MS, Nagai S. Center experience affects liver transplant outcomes in patients with hilar cholangiocarcinoma. Ann Surg Oncol. 2020;27:5209–5221

Article  PubMed  Google Scholar 

Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88–98

Article  PubMed  Google Scholar 

Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer. 2016;16:322

Article  PubMed Central  PubMed  Google Scholar 

Yang W, Sun Y. Promising molecular targets for the targeted therapy of biliary tract cancers: an overview. Onco Targets Ther. 2021;14:1341–1366

Article  PubMed Central  PubMed  Google Scholar 

Wu C-E, Chen M-H, Yeh C-N. mTOR inhibitors in advanced biliary tract cancers. Int J Mol Sci. 2019;20:500

Article  CAS  PubMed Central  PubMed  Google Scholar 

Dondorf F, Uteβ F, Fahrner R, Felgendreff P, Ardelt M, Tautenhahn HM, et al. Liver transplant for perihilar cholangiocarcinoma (Klatskin tumor): the essential role of patient selection. Exp Clin Transplant. 2019;17:363–369

Article  PubMed  Google Scholar 

Cameron S, Ramadori G, Füzesi L, Sattler B, Gunawan B, Müller D, et al. Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. Transplantation. 2005;80:283–284

Article  PubMed  Google Scholar 

Duan Y, Haybaeck J, Yang Z. Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers. 2020;12:2972